NOVOSEVEN 1 mg (50 KUI) POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE

USDailyMed:Coagulation factor VIIa (recombinant) AU:B1 B02BD08(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 102786-61-8Y DB00036 none AC71R787OV D00172 Recombinant factor VIIa(rfVIIa) is a form of bloodfactor VIIthat has been manufactured viarecombinant technology.It is administered via aninjection into a vein.It is used to treat bleeding episodes in people who haveacquired hemophilia, among other indications. The most common side effects with Novoseven includevenous thromboembolic events(problems caused by blood clots in the veins), rash,pruritus(itching),urticaria(hives),feverand reduced effectiveness of treatment.The most common side effects with Cevenfacta include injection site discomfort andhematoma(a collection of blood under the skin) as well as injection-related reactions, an increase in body temperature, dizziness and headache. Novoseven was authorized for medical use in the European Union in February 1996,and in the United States in March 1999.